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The Basics of Bacteriuria: Strategies
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Bacteriuria, the presence of bacteria in urine, is associated with asymptomatic, as well
as symptomatic, urinary tract infection (UTI). Bacteriuria underpins some of the dynamics
of microbial colonization of the urinary tract, and probably impacts the progression and
persistence of infection in some individuals. Recent molecular discoveries in vitro have
elucidated how some key bacterial traits can enable organisms to survive and grow
in human urine as a means of microbial fitness adaptation for UTI. Several microbial
characteristics that confer bacteruric potential have been identified including de novo
synthesis of guanine, relative resistance to D-serine, and catabolism of malic acid.
Microbial characteristics such as these are increasingly being defined through the use
of synthetic human urine (SHU) in vitro as a model to mimic the in vivo environment
that bacteria encounter in the bladder. There is considerable variation in the SHU model
systems that have been used to study bacteriuria to date, and this influences the
utility of these models. In this review, we discuss recent advances in our understanding
of bacteruric potential with a focus on the specific mechanisms underlying traits that
promote the growth of bacteria in urine. We also review the application of SHU in research
studies modeling UTI and discuss the chemical makeup, and benefits and limitations that
are encountered in utilizing SHU to study bacterial growth in urine in vitro.
Keywords: bacteriuria, asymptomatic bacteriuria, urinary tract infection, urine, urinalysis, uropathogen, synthetic
human urine, artificial urine
INTRODUCTION: BACTERIURIA AND URINARY TRACT
INFECTION
“Asymptomatic Bacteriuria” (ABU or ASB) is synonymous with asymptomatic Urinary Tract
Infection (UTI) in defining the isolation of a specified semi-quantitative count of bacteria in an
appropriately collected urine specimen from a person without signs or symptoms related to UTI
(Rubin et al., 1992; Nicolle et al., 2005). Bacteriuria is a marker for symptomatic UTI (sUTI)
and assists in grading the severity of infection. Establishment of bacteriuria depends on entry
of an organism with bacteruric potential into the urinary tract and can persist for months or
years. Bacteruric potential encompasses microbial survival, growth, and re-growth in urine, and
endurance of host defense mechanisms including dilution, voiding, frequent flushing (O’grady
and Cattell, 1966a,b), and antimicrobial constituents such as Tamm-Horsfall glycoprotein (aka
uromodulin), and P blood group antigen (Hand et al., 1971; Lomberg et al., 1983; Bates et al.,
2004). Bacteruric potential can thus influence the persistence of ABU and sUTI. Here, we analyze
the differences in microbial strategies used for growth in urine and the methods for modeling
bacteriuria using synthetic human urine (SHU).
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MICROBIAL BACTERURIC POTENTIAL
AND HOST DYNAMICS
Recent reviews have focused on the pathogenesis of acute sUTI
(Nielubowicz and Mobley, 2010; Hannan et al., 2012; Ulett et al.,
2013), and ABU (Ipe et al., 2013; Schneeberger et al., 2014)
and will not be revisited here. We will focus on bacteriuria
specifically; the progression of which depends on microbe traits
as well as host factors. Most individuals who suffer persistent
UTI do not harbor the same strain of organism over time
(Hooton et al., 2000), implying that turnover of causal organisms
is dynamic. Replacement of colonizing strains during bacteriuria
has been studied for Escherichia coli, the most common cause
of ABU (Ipe et al., 2013). Long-term bacteriuria appears to
select for attenuated virulence phenotypes of colonizing strains
(Salvador et al., 2012). While most microbes are killed by urine,
different organisms have distinct bacteruric potential. Several
traits can affect microbial growth in urine. Antibiotics stop
the progression of bacteriuria (Schneeberger et al., 2012) but
patients infected with E. coli experience re-colonization with
the same or similar organism at high rates (Dalal et al., 2009).
This highlights the dynamic nature of bacteriuria and the role
of therapeutic intervention [that is not recommended as routine
for ABU (Nicolle, 2014)]. Other factors that are associated
with the promotion of long-term bacteriuria are defects in
immune signaling pathways such as TLRs (Ragnarsdóttir and
Svanborg, 2012). Thus, persistence of bacteriuria relates to
microbial bacteruric potential and host characteristics/dynamics
including genetic immunodeficiency, re-current infection or
strain replacement, and antibiotic therapy.
Microbial Metabolism and Growth Fitness
in Urine: Knowledge from E. coli
The progression of bacteriuria depends on a microbes’ ability
to survive the antimicrobial properties of urine. Urine survival
and growth maintains a pool of colonizing organisms regardless
of adherence to host cells, and urodynamic properties (urine
flow rates, voiding) that differ between individuals (Wullt et al.,
1998). Non-voided organisms in residual urine can grow and
re-grow to maintain infection. Discoveries using ABU microbes
have shaped our understanding of how bacteriuria progresses.
ABU E. coli strain 83972 displays robust fitness for urine growth
(Klemm et al., 2006; Roos et al., 2006b) though this is not a
defining feature of all ABU E. coli, and is observed in some
uropathogenic E. coli (UPEC) (Stamey and Mihara, 1980; Alteri
and Mobley, 2007; Alteri et al., 2009; Aubron et al., 2012). Poor
urine growth has been reported for some fecal E. coli isolates
(Stamey and Mihara, 1980; Gordon and Riley, 1992). ABU E.
coli 83972 has been investigated as a prophylactic means to treat
acute sUTI (Hull et al., 2000; Wullt, 2003; Roos et al., 2006a;
Sundén et al., 2006; Klemm et al., 2007; Watts et al., 2012a).
The metabolic basis for urine growth of ABU E. coli 83972
involves transport and degradation pathways for galacturonate,
glucuronide and galactonate (Roos et al., 2006b), and antioxidant
defense mechanisms (Aubron et al., 2012); the details are
described elsewhere (Roos et al., 2006a,b). More recently, analysis
of ABU E. coli 83972 re-isolates indicated marked versatility
of metabolic pathways in urine, including utilization of amino
acids, hexuronates or (deoxy-) ribonucleosides as an adaptation
to individual hosts (Zdziarski et al., 2010). This underlines the
metabolic versatility of E. coli in urine in response to host-
specific metabolic constraints. guaA and argC were shown to
be critical for urine growth and a lack of urinary guanine (or
derivatives), combined with an inability of E. coli to synthesize
these compounds de novo, prevents the synthesis of other
guanine (or derivative)-dependent products that are required
for growth (Russo et al., 1996). Separate from guanine, argC
and carAB mutants had reduced growth in urine in a E. coli
transposon mutagenesis study, illustrating a role for arginine
metabolism (Vejborg et al., 2012).
Knowledge from Bacteria other than E. coli
Clinical isolates of Enterococcus faecalis, Proteus vulgaris,
Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus
saprophyticus, and Streptococcus agalactiae have been shown
to grow in human urine (Table 1). However, little is known
about the mechanisms used by these organisms for urine
growth. For E. faecalis there are some similarities to E. coli;
E. faecalis expresses multiple virulence genes in urine (Shepard
and Gilmore, 2002) including genes for iron transport (Vebø
et al., 2010). Iron utilization mechanisms have been reported in
urine growth assays with E. coli (Watts et al., 2012b). Limiting
manganese may be important in restricting E. faecalis urine
growth (Järvisalo et al., 1992; Low et al., 2003; Vebø et al.,
2010). In contrast to activation of pathways described for E.
coli, E. faecalis activates citrate and aspartate metabolic pathways,
and represses glucose uptake (Vebø et al., 2010). Human urine
contains more citrate than glucose (Shaykhutdinov et al., 2009;
Wishart et al., 2009; Bouatra et al., 2013), which could promote
growth of E. faecalis. However, human urine is highly variable
in chemical constituency and different levels of components
such as glucose may influence microbial growth; for example,
glucosuria enhances growth of E. coli. E. faecalis also upregulates
genes for utilization of sucrose (and perhaps fructose), another
constituent of urine (Tasevska et al., 2005; Bouatra et al., 2013).
Other E. faecalis genes thought to function in urine growth
include those related to import of phosphorylated sugars and
glycerol, N-acetyl glucosamine metabolism (Vebø et al., 2010),
cysteine synthase, and pathways for conversion of aspartate and
α-ketoglutarate to oxaloacetate and glutamate. Urinary aspartate
may be used for nitrogen metabolism (Guo and Li, 2009). E.
faecalis is auxotrophic for multiple amino acids but human
urine contains several amino acids including arginine, glutamate,
glycine, and leucine (Guo and Li, 2009; Bouatra et al., 2013).
An analysis of metabolic traits of P. aeruginosa using synthetic
urine revealed adaptation in central metabolism to lactate, citrate,
and amino acids as carbon sources, and the induction of amino
acid utilization pathways (Tielen et al., 2013). Metabolic flux
analysis showed the use of the Entner-Doudoroff pathway with
respiratory metabolism, with the pentose phosphate pathway
being used exclusively for biosynthesis. Flux through pyruvate
metabolism, the tricarboxylic acid cycle, and the glyoxylate shunt
was highly variable, and likely caused by adaptive processes in
individual strains during infection (Berger et al., 2014).
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TABLE 1 | Summary of traits that contribute to bacteruric potential in microbes.
Trait that confers bacteruric potential Bacterial species References
Ability to utilize human urine as a substrate for growth E. coli Gordon and Riley, 1992; Russo et al., 1996; Roesch et al., 2003; Snyder
et al., 2004; Johnson et al., 2006; Roos et al., 2006a; Alteri and Mobley, 2007;
Klemm et al., 2007; Aubron et al., 2012; Vejborg et al., 2012; Watts et al.,
2012b; Hryckowian et al., 2015; King et al., 2015; Shields-Cutler et al., 2015
E. faecalis Shepard and Gilmore, 2002; Vebø et al., 2010; La Rosa et al., 2012
P. vulgaris Nickel et al., 1985; Carlsson et al., 2001
P. aeruginosa Nickel et al., 1985; Carlsson et al., 2001; Storer et al., 2011
K. pneumoniae Storer et al., 2011; Russo et al., 2015
S. saprophyticus Sakinç et al., 2009
S. agalactiae Ipe et al., 2016
Tolerance to high levels of D-serine S. saprophyticus Sakinç et al., 2009
Requirement for dsda for rapid urine growth E. coli Hryckowian et al., 2015
Capacity for synthesis of guanine-dependent products critical
for survival in urine
E. coli Russo et al., 1996
Expression of iron acquisition systems for growth in nutrient
limiting environment
E. coli Alteri and Mobley, 2007; Watts et al., 2012b; Shields-Cutler et al., 2015
E. faecalis Vebø et al., 2010
Osmoadaption, and intracellular accumulation of glycine
betaine
E. coli Chambers and Lever, 1996; Deutch et al., 2006
Adaptation of central metabolism to lactate, citrate and amino
acids as carbon sources; flux through pyruvate metabolism,
TCA cycle
P. aeruginosa Tielen et al., 2013; Berger et al., 2014
Malic acid metabolism S. agalactiae Ipe et al., 2016
Phenotype metabolic arrays were recently reported for ABU
S. agalactiae (Ipe et al., 2016). Comparison with S. agalactiae
strains that were unable to grow in urine showed that malic
acid catabolism was important for growth in urine. Malic acid
utilization is related to the malic enzyme metabolic pathway that
catalyzes the oxidative decarboxylation of malate (a component
of human urine depending on diet) to pyruvate and CO2. This is
related to malolactic fermentation, a bacterial metabolic process
typically associated with wine deacidification (Landete et al.,
2010).
Three Ways to Survive in Urine: Resistance,
Acquisition, and Osmoadaption
Urine is naturally antimicrobial; hypertonicity with low pH
(averaging ∼6.0) and high concentrations of urea inhibit most
bacteria (Chambers and Lever, 1996; Kucheria et al., 2005).
Nitrite in mildly acidified urine inhibits the growth of some
uropathogens (Carlsson et al., 2001), and other abundant
proteins such as Tamm-Horsfall glycoprotein are antimicrobial
(Raffi et al., 2005; Säemann et al., 2005). Recently, the
antimicrobial properties of urine were shown to include specific
inhibition of both expression and function of UPEC type 1
pili (Greene et al., 2015), and downregulation of capsule genes
(King et al., 2015). Individualistic urinary chemical features can
also affect the antimicrobial properties of some antimicrobial
urinary proteins such as siderocalin (Shields-Cutler et al., 2015).
Bacteria that can endure urine antimicrobial properties do so
through various means; for example, S. saprophyticus tolerates
high concentrations of D-serine, which is abundant in urine and
bacteriostatic toward organisms that lack a D-serine deaminase
(Cosloy and McFall, 1973; Hryckowian et al., 2015). Iron
limitation and the presence iron chelators such as lactoferrin
(Weinberg, 1978) compounds the problem of nutritional
immunity for microbes (Hood and Skaar, 2012) especially during
states of increased iron chelator production (Gonzalez-Chavez
et al., 2009; Soler-García et al., 2009). Siderophores confer
bacteruric potential to E. coli (Håversen et al., 2000; Snyder
et al., 2004; Alteri and Mobley, 2007; Hagan and Mobley, 2009;
Garcia et al., 2011; Watts et al., 2012b) and several genes
encoding factors involved in iron transport are upregulated in
E. faecalis during urine growth (Vebø et al., 2010). Siderophores
may also act as ligands for cations other than iron, such as
copper (Chaturvedi et al., 2012). Variable resistance to urinary
defense molecules (e.g., nitrite, ascorbic acid) could influence
bacteruric potential but little is known beyond the effects of these
toward the chemical properties of urine (Carlsson et al., 2001).
Finally, many organisms are probably unable to survive the
oxygen concentrations encountered in the bladder (Leonhardt
and Landes, 1963; Clarke et al., 1985).
Urea is abundant in urine and is antibacterial (Sobel, 1985).
Osmoadaptive systems enable some bacteria to survive the
stressful hypertonic conditions of urine. Bacterial accumulation
of osmotically compatible solutes that are present in urine (e.g.,
betaines) confers bacteruric potential by effectively enabling
microbes to resist dehydration (Chambers and Lever, 1996;
Deutch et al., 2006). Osmoadaptive systems respond to changes
in tonicity in urine, and support survival by counteracting
low pH, high urea concentrations and hypertonicity (Chambers
and Lever, 1996). For E. coli, glycine betaine is a central
osmoprotectant to resist urea toxicity, and its accumulation is
essential to adaptive responses to osmotic stress (Kunin et al.,
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1992; Chambers and Lever, 1996). E. coli increases the activity
of potassium transport systems that encompass TrkG, TrkH,
and Kup (Meury et al., 1985), or Kdp (Laimins et al., 1978)
to counteract osmotic stress. Other systems involve trehalose as
an organic osmolyte; its induction is triggered in conditions of
high potassium (and glutamate) (Strøm and Kaasen, 1993), and
its accumulation elicits the release of potassium from the cell
(Dinnbier et al., 1988). This might aid growth since trehalose
can be used as a carbon source (Gutierrez et al., 1989; Styrvold
and Strøm, 1991). OmpR regulates osmoadaptive genes in E. coli
(Barron et al., 1986). Osmotic stress suppresses the expression
of fimbriae and flagellin (Kunin et al., 1994, 1995). Future
studies of bacteria other than E. coli that can grow in urine
will elucidate additional mechanisms of resistance to urinary
antimicrobial properties, nutrient acquisition and metabolism,
and osmoadaption.
Between a Rock and a Hard-Place: The
Bladder Mucosa-Lumen Interface of
Immune Surveillance and Bacteriuria
Inflammation is a critical part of sUTI pathogenesis (Hannan
et al., 2012; Ulett et al., 2013) and involves thousands of genes
that drive antibacterial responses within hours of infection
(Duell et al., 2012; Tan et al., 2012; Carey et al., 2016). For
example, antimicrobial peptides produced by the bladder are
important for protection against infection (Chromek et al.,
2006). Microbes must survive these inflammatory events.
Urine is a “Hard-place” for microbes to survive, as discussed
above. Tissue inflammation in the bladder represents a “rock”
of antimicrobial responses for defense against UTI and, for
ABU, can encompass pyuria, cytokine release (IL-1α, -6, and
-8), and antibody production, which has been documented in
elderly adults, as reviewed elsewhere (Nicolle, 1997). Excessive
inflammation may contribute to chronic sUTI (Hannan et al.,
2010) and some acute sUTI symptoms have been linked to
specific inflammatory events (Rudick et al., 2010). However,
the benign, minimally inflammatory nature of ABU is reflected
in the lack of morbidity in individuals who do not receive
therapy (Nicolle, 1997, 1999; Ariathianto, 2011). Details of
how ABU bacteria induce and minimize inflammation offer
insight into how microbial modulation of host defense may
promote bacteriuria. ABU E. coli minimizes inflammation by
averting adherence due to a lack of fimbriae expression; this
limits immune activation (Roos et al., 2006b) and results in
long-term ABU (Arthur et al., 1989; Andersson et al., 1991).
Grönberg-Hernandez et al. showed that ABU E. coli activates
IRF3 and TLR4-dependent signaling, however, triggering a
response that depends on host genetic background (Grönberg-
Hernández et al., 2011); the IRF3-dependent signaling pathway
is critical for distinguishing pathogens from the normal flora
(Fischer et al., 2010). TLR4 senses P-fimbriated E. coli (Frendéus
et al., 2001), and TLR4 mutations may favor ABU by impeding
innate responses (Svanborg et al., 2006). This raises the question
of whether ABU may influence subsequent encounter(s) with
other uropathogens. One study on streptococcal UTI showed an
influence on the severity of subsequent E. coliUTI in mice (Kline
et al., 2012). Thus, immune activation triggered by ABU might
affect subsequent sUTI caused by diverse pathogens. These data
offer some parallel to clinical observations that patients with E.
coli ABU suffer re-colonization at high rates following therapy
(Dalal et al., 2009).
MODELING BACTERIURIA IN VITRO:
SYNTHETIC HUMAN URINE (SHU)
Urine is unique from a microbial perspective and its chemical
makeup, distinct from all other bodily fluids, has been modeled
for studying the growth of microbes for 50 years (O’grady and
Pennington, 1966). Urine has a low pH and a high osmolality due
to the presence of salts and urea (Kucheria et al., 2005; Sheewin,
2011). The peptides, proteins, and organic acids present in urine
may be metabolized by microbes (Decramer et al., 2008). Urine
is dynamic in flow rate and composition, which changes subject
to diet, age, gender and health status, and disease. Decreased
levels of THP, for example, are associated with diabetes (Torffvit
and Agardh, 1993) and infection (Ronald and Ludwig, 2001).
Data on microbial traits that afford bacteruric potential have, in
many cases, been derived from studies using SHU. Eight original
SHU media recipes were described between 1971 and 2010: as
summarized according to research application and composition
in Table 2.
SHU offers several advantages compared to normal human
urine collected from healthy adults for research assays ex vivo;
it avoids the issue of variable chemical composition encountered
with fresh human urine; variation in urinary constituents
between individuals (Bouatra et al., 2013) is a challenge
for standardizing research studies. Methods for “normalizing”
fresh human urine include pooling samples and adjusting
dilution/concentration according to creatinine concentration,
specific gravity, and osmolality. The most widely used method is
creatinine adjustment (Barr et al., 2005), however no bacteriuria
research studies to date have applied these methods for
normalizing, and the effects on data interpretation are unknown.
Volume limits have been difficult for some studies (Davis et al.,
1982). As a surrogate model, the benefits of SHU are defined by
how closely it can reflect the chemical complexity of fresh human
urine. Urine from a healthy adult contains glucose (0.2–0.6mM)
(Shaykhutdinov et al., 2009), creatine (0.38–55.6mM; Barr et al.,
2005; Shaykhutdinov et al., 2009), and glycine with low levels of
other amino acids such as D-serine (Huang et al., 1998; Pätzold
et al., 2005), histidine, glutamine, methionine, proline, glutamate,
arginine, cysteine, and branched chain amino acids (Guo and Li,
2009; Vebø et al., 2010). It contains trace fatty acids, citrate (1.0–
2.0mM) (Wishart et al., 2009), sucrose (70–200µM) (Tasevska
et al., 2005), and manganese (nM range) (Järvisalo et al., 1992).
To standardize SHU composition for bacteriuria studies,
we propose a composite SHU medium recipe (Table 2), and
compare this to descriptions of “typical human urine” (Putnam
et al., 1971; Bouatra et al., 2013). Examples of supplements
to previously used SHU formulations include Lysogeny Broth
(LB), Todd-Hewitt Broth (THB), and dextrose for fungi
such as Candida sp. (Table 2). The proposed composite SHU
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TABLE 2 | Original and subsequent studies using Synthetic Human Urine (SHU) (A), and related SHU constituents, and proposed composite SHU (B).
A. Original study1 Focus of the
research application








N/A Urolithiasis Mayrovitz and Sims, 2001
2. Infection (Brooks
and Keevil, 1997)
Development of SHU to
investigate the growth
of urinary pathogens
E. coli, P. aeruginosa, P.
mirabilis, S. epidermidis, C.
albicans
UTI Darouiche et al., 2008; Wernli et al., 2013; Azevedo





SHU for in vitro
urolithiasis assays
N/A Urolithiasis Brown et al., 1989; Rodgers and Wandt, 1991;
Opalko et al., 1997; Mayrovitz and Sims, 2001;
Christmas et al., 2002; 2(Isaacson, 1969; Barker
et al., 1974; Rose, 1975; Miller et al., 1977;





SHU media, and study
in epithelial cell culture
assays
Kidney epithelial cells Cell Biology 2,3(Brown et al., 1989; Brooks and Keevil, 1997;
Opalko et al., 1997; Grases and Llobera, 1998;
Mayrovitz and Sims, 2001; Christmas et al., 2002);












UTI, and Urolithiasis Davis et al., 1989, 1991; Martino et al., 2003;
Dalhoff et al., 2011; Phuengkham and Nasongkla,
2015. 4Cited by: (Domergue et al., 2005; Mabbett
et al., 2009; Ong et al., 2009, 2010). 4Cited by:
(Watts et al., 2010; Jain et al., 2007). 4Cited by:
(Silva et al., 2010; Rane et al., 2014; Negri et al.,
















N/A Urolithiasis Robertson et al., 1981. 4Cited by: (Robertson and
Scurr, 1986)
B. Constituent (n)5 Mean Conc. (Range)6 Composite7 References Citing Constituent
NaCl 8/8 113.3 (54–231) mM 100mM Griffith et al., 1976; Minuth et al., 1976; Gardner and
Doremus, 1978; Aurora et al., 1980; Burns and
Finlayson, 1980; Robertson and Scurr, 1986;
Brooks and Keevil, 1997; Chutipongtanate and
Thongboonkerd, 2010
Na2SO4 8/8 17.0 (9.0–155,800) mM 17.0mM Griffith et al., 1976; Minuth et al., 1976; Gardner and
Doremus, 1978; Aurora et al., 1980; Burns and
Finlayson, 1980; Robertson and Scurr, 1986;
Brooks and Keevil, 1997; Chutipongtanate and
Thongboonkerd, 2010
pH 7/8 6.0 (5.7–7.2) 5.5–6.0 Griffith et al., 1976; Minuth et al., 1976; Gardner and
Doremus, 1978; Burns and Finlayson, 1980;
Robertson and Scurr, 1986; Brooks and Keevil,
1997; Chutipongtanate and Thongboonkerd, 2010
Urea 6/8 281 (170–500) mM 280mM Griffith et al., 1976; Minuth et al., 1976; Gardner and
Doremus, 1978; Aurora et al., 1980; Brooks and
Keevil, 1997; Chutipongtanate and Thongboonkerd,
2010
KCl 6/8 58.5 (21.5–162.7) mM 38.0mM Griffith et al., 1976; Minuth et al., 1976; Aurora
et al., 1980; Burns and Finlayson, 1980; Robertson
and Scurr, 1986; Chutipongtanate and
Thongboonkerd, 2010
CaCl2 6/8 5.3 (2.5–12.0) mM 4.0mM Griffith et al., 1976; Minuth et al., 1976; Burns and
Finlayson, 1980; Robertson and Scurr, 1986;
Brooks and Keevil, 1997; Chutipongtanate and
Thongboonkerd, 2010
(Continued)
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 February 2016 | Volume 6 | Article 14
Ipe et al. Basics of Bacteriuria
TABLE 2 | Continued
B. Constituent (n)5 Mean Conc. (Range)6 Composite7 References Citing Constituent
Creatinine 5/8 8.7 (4.0–13.2) mM 9.0mM Griffith et al., 1976; Minuth et al., 1976; Aurora
et al., 1980; Brooks and Keevil, 1997;
Chutipongtanate and Thongboonkerd, 2010
Na3C6H5O7 5/8 3.4 (2.2–5.0) mM 3.4mM Griffith et al., 1976; Minuth et al., 1976; Burns and
Finlayson, 1980; Robertson and Scurr, 1986;
Chutipongtanate and Thongboonkerd, 2010
NH4Cl 5/8 36.6 (15.0–86.8) mM 20.0mM Griffith et al., 1976; Minuth et al., 1976; Robertson
and Scurr, 1986; Brooks and Keevil, 1997;
Chutipongtanate and Thongboonkerd, 2010
MgSO4 5/8 3.2 (2.0–5.9) mM 3.2mM Aurora et al., 1980; Burns and Finlayson, 1980;
Robertson and Scurr, 1986; Brooks and Keevil,
1997; Chutipongtanate and Thongboonkerd, 2010
Na2C2O4 5/8 0.38 (0.1–1.2) mM 0.18mM Griffith et al., 1976; Minuth et al., 1976; Burns and
Finlayson, 1980; Chutipongtanate and
Thongboonkerd, 2010
NaH2PO4 4/8 20.9 (3.6–43.6) mM 3.6mM Aurora et al., 1980; Burns and Finlayson, 1980;
Robertson and Scurr, 1986; Chutipongtanate and
Thongboonkerd, 2010
Na2HPO4 4/8 6.5 (6.1–186,800) mM 6.5mM Gardner and Doremus, 1978; Aurora et al., 1980;
Robertson and Scurr, 1986; Chutipongtanate and
Thongboonkerd, 2010
KH2PO4 3/8 16.0 (7.0–20.6) mM 16.0mM Griffith et al., 1976; Minuth et al., 1976; Brooks and
Keevil, 1997
C5H4N4O3 3/8 0.6 (0.4–1.0) mM 0.6mM Aurora et al., 1980; Brooks and Keevil, 1997;
Chutipongtanate and Thongboonkerd, 2010
NaHCO3 2/8 13.5 (2.0–25.0) mM 13.5mM Brooks and Keevil, 1997; Chutipongtanate and
Thongboonkerd, 2010
MgCl2.6H2O 2/8 3.2 (3.2) mM 3.2mM Griffith et al., 1976; Minuth et al., 1976
Osmolality 2/8 586 (446–725) mOsm/kg 600 mOsm/kg Minuth et al., 1976; Chutipongtanate and
Thongboonkerd, 2010
C6H8O7 2/8 1.7 (1.4–2.0) mM – Aurora et al., 1980; Brooks and Keevil, 1997
TSB8 2/8 2.0% (1.0–5.0%) (v/v) – Griffith et al., 1976; Minuth et al., 1976; Torzewska
et al., 2003, 2014; Torzewska and Rózalski, 2014,
2015
NH3OH 1/8 17.1mM – Aurora et al., 1980
C9H9NO3 1/8 2.8mM – Aurora et al., 1980
K2HPO4 1/8 7.0mM – Brooks and Keevil, 1997
C3H6O3 1/8 1.1mM 1.1mM Brooks and Keevil, 1997
FeSO4.7H2O 1/8 0.005mM 0.005mM Brooks and Keevil, 1997
K3C6H5O7 1/8 2752000mM – Gardner and Doremus, 1978
Mg(NO3)2 1/8 2.5mM – Gardner and Doremus, 1978
Peptone8 1/8 0.1% (w/v) – Brooks and Keevil, 1997
Yeast extract8 1/8 0.0005% (w/v) – Brooks and Keevil, 1997
Glucose 0/8 1.0% (0.3–2.0%) (w/v) – Uppuluri et al., 2009; Silva et al., 2010; Negri et al.,
2012, 2015
Sucrose 0/8 0.002% (w/v) – Wernli et al., 2013
Lactose 0/8 0.002% (w/v) – Wernli et al., 2013
LB8 0/8 3.5% (2.5–5.0%) (v/v) – Martino et al., 2003; Domergue et al., 2005;
Wenzler-Röttele et al., 2006; Ong et al., 2009,
2010; Ipe et al., 2016
Dextrose8 0/8 3.4% (0.3–8.0%) (w/v) – Domergue et al., 2005; Jain et al., 2007; Negri
et al., 2011
THB8 0/8 2.5% (v/v) – Ipe et al., 2016
YNB8 0/8 5.0% (5.0–5.0%) (v/v) – Jain et al., 2007; Uppuluri et al., 2009
SC Broth8 0/8 5.0% (v/v) – Domergue et al., 2005
(Continued)
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TABLE 2 | Continued
B. Constituent (n)5 Mean Conc. (Range)6 Composite7 References Citing Constituent
Nutrient Broth8 0/8 1.2% (0.4–2.0%) (v/v) – Wenzler-Röttele et al., 2006; Sako et al., 2014
Gelatine8 0/8 1.0% (w/v) – Wenzler-Röttele et al., 2006
Casamino Acids,
Bacto8
0/8 – 0.1% (v/v)
1Original study of Robinson et al. (1984) cited by Lee et al. (1995) does not provide a recipe; 2Reference(s) included in original study (minimal recipe details in reference citing original
study); 3Original studies of Brooks and Keevil (1997) and Grases and Llobera (1998) cited by Chutipongtanate and Thongboonkerd (2010) provide a recipe; 4Cited by: these references
cite the immediate preceding reference rather than the original study; 5The number of original studies (n/8) that defined the component in their SHU recipe; 6Refers to Average
Concentration, and (Concentration Range). Study of Robertson and Scurr (1986) was used to calculate Mean Concentration, and (Concentration Range) instead of Original Study of
Putnam et al. (1971) because Putnam et al. (1971) does not provide a SHU recipe; 7Proposed Composite SHU Media Concentrations are based on average values in referenced
studies, and most compare closely to the typical human urine chemical composition as reported in Putnam et al. (1971) (e.g., NaCl 137mM, Urea 223mM, KCl 22mM, Creatinine
13.3mM, MgSO4 6.5mM). In some cases (e.g., Na2HPO4, Na2SO4, KCl, Na2C2O4) the means and composite SHU values are chosen to exclude extreme upper range values from
Gardner and Doremus (1978), Robertson and Scurr (1986). 8References cited for components are original studies only, excepting for these components, for which all published studies
using these components are cited. The proposed composite SHU omits Trypticase Soy Broth (TSB), peptone, LB, THB, and Nutrient Broth (undefined), Yeast Nitrogen Base (YNB) and
Synthetic Complete (SC) Broth (for fungi), but includes 0.1% v/v Casamino Acids, Bacto (20% stock solution; BD) to attain a chemically defined minimal SHU medium, with the addition
of 0.2% v/v (10% stock solution) yeast extract as a proposed supplement for fastidious bacteria including Streptococcus, or 2.0% w/v dextrose and 5.0% v/v YNB for fungi.
medium omits chemically undefined components such as LB to
provide chemical definition, is easily prepared, inexpensive, and
chemically stable. However, it is also not without its limitations;
it excludes some natural constituents of human urine such
as hormones, iron chelators, and pyrophosphates that could
influence microbial growth. The relative concentrations of some
urinary constituents differ between males and females (e.g., less
calcium and oxalate, more citrate excretion in women, more
creatinine in men; Ryall et al., 1987; Sarada and Satyanarayana,
1991; Bouatra et al., 2013) and the proposed composite SHU
does not account for these differences. Nonetheless, as a
balance between feasibility, logistics, and economy the proposed
composite SHUmedium should be of value to standardize future
bacteriuria studies; importantly, studies will now need to validate
the proposed composite SHU medium using a range of relevant
bacteria, and in particular, analyze the need for supplements (e.g.,




A capacity of microorganisms for urine growth may aid in
establishing long-term bacteriuria and is relevant to many
microbial species. New discoveries on immune activation by
ABU show this form of infection does not exist entirely under the
radar of immune surveillance. Continued use of SHU for in vitro
studies will drive new discoveries on how bacteriuria progresses
and how this may influence subsequent infection. Future work
needs to address multiple areas; including (1) validation of the
proposed composite SHU medium using a range of relevant
bacteria; (2) defining differences in “significant” bacteriuria for
different organisms and the implications of bacteruric potential
toward such definitions; (3) lifestyle adaptations, other than those
described for D-serine, guanine, malic acid, and iron acquisition
that aid microbial bacteruric potential; (4) the molecular basis
of urine growth in non-E. coli organisms; how ABU interfaces
with host immune mechanisms for different organisms (and
among distinct patient populations); (5) differences in male
vs. female urine composition, in particular hormones (and
whether this influences bacterial growth); and (6) how ABU
impacts on subsequent UTI including comparisons of immune
responses to ABU caused by organisms other than E. coli. How
effective ABU might be as a prophylactic approach against
sUTI continues to be a topic for future investigation. More
importantly, studies aimed at defining bacterial mechanisms
that are critical for growth in urine are essential in the context
of providing a foundation for novel treatment and preventive
strategies.
AUTHOR CONTRIBUTIONS
DI, EH, and GU conceived of the study, analyzed the literature,
and wrote the manuscript.
ACKNOWLEDGMENTS
This work was supported by an Australian National Health and
Medical Research Council (NHMRC) grant (APP1084889) (GU),
and a Griffith University New Researcher Grant (219152) (DI).
GU is supported by a Future Fellowship from the Australian
Research Council (FT110101048).
REFERENCES
Alteri, C. J., and Mobley, H. L. (2007). Quantitative profile of the
uropathogenic Escherichia coli outer membrane proteome during growth
in human urine. Infect. Immun. 75, 2679–2688. doi: 10.1128/IAI.
00076-06
Alteri, C. J., Smith, S. N., and Mobley, H. L. (2009). Fitness of Escherichia coli
during urinary tract infection requires gluconeogenesis and the TCA cycle.
PLoS Pathog. 5:e1000448. doi: 10.1371/journal.ppat.1000448
Andersson, P., Engberg, I., Lidin-Janson, G., Lincoln, K., Hull, R., Hull, S., et al.
(1991). Persistence of Escherichia coli bacteriuria is not determined by bacterial
adherence. Infect. Immun. 59, 2915–2921.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 February 2016 | Volume 6 | Article 14
Ipe et al. Basics of Bacteriuria
Ariathianto, Y. (2011). Asymptomatic bacteriuria - prevalence in the elderly
population. Aust. Fam. Physician 40, 805–809.
Arthur, M., Johnson, C. E., Rubin, R. H., Arbeit, R. D., Campanelli, C., Kim,
C., et al. (1989). Molecular epidemiology of adhesin and hemolysin virulence
factors among uropathogenic Escherichia coli. Infect. Immun. 57, 303–313.
Aubron, C., Glodt, J., Matar, C., Huet, O., Borderie, D., Dobrindt, U., et al. (2012).
Variation in endogenous oxidative stress in Escherichia coli natural isolates
during growth in urine. BMCMicrobiol. 12:120. doi: 10.1186/1471-2180-12-120
Aurora, A. L., Rao, A. S., and Srimathi, V. (1980). Effects of constituents of
artificial urine on spontaneous precipitation of calcium oxalate monohydrate
(whewellite). Ind. J. Med. Res. 72, 273–283.
Azevedo, A. S., Almeida, C., Melo, L. F., and Azevedo, N. F. (2014). Interaction
between atypical microorganisms and E. coli in catheter-associated urinary tract
biofilms. Biofouling 30, 893–902. doi: 10.1080/08927014.2014.944173
Barker, L. M., Pallante, S. L., Eisenberg, H., Joule, J. A., Becker, G. L., and Howard,
J. E. (1974). Simple synthetic and natural urines have equivalent anticalcifying
properties. Invest. Urol. 12, 79–81.
Barr, D. B., Wilder, L. C., Caudill, S. P., Gonzalez, A. J., Needham, L. L., and
Pirkle, J. L. (2005). Urinary creatinine concentrations in the U.S. population:
implications for urinary biologic monitoring measurements. Environ. Health
Perspect. 113, 192–200. doi: 10.1289/ehp.7337
Barron, A., May, G., Bremer, E., and Villarejo, M. (1986). Regulation of envelope
protein composition during adaptation to osmotic stress in Escherichia coli.
J. Bacteriol. 167, 433–438.
Bates, J. M., Raffi, H. M., Prasadan, K., Mascarenhas, R., Laszik, Z., Maeda,
N., et al. (2004). Tamm-Horsfall protein knockout mice are more prone to
urinary tract infection: rapid communication. Kidney Int. 65, 791–797. doi:
10.1111/j.1523-1755.2004.00452.x
Berger, A., Dohnt, K., Tielen, P., Jahn, D., Becker, J., and Wittmann,
C. (2014). Robustness and plasticity of metabolic pathway flux among
uropathogenic isolates of Pseudomonas aeruginosa. PLoS ONE 9:e88368. doi:
10.1371/journal.pone.0088368
Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C.,
et al. (2013). The human urine metabolome. PLoS ONE 8:e73076. doi:
10.1371/journal.pone.0073076
Brooks, T., and Keevil, C. W. (1997). A simple artificial urine for the growth
of urinary pathogens. Lett. Appl. Microbiol. 24, 203–206. doi: 10.1046/j.1472-
765X.1997.00378.x
Brown, P., Ackermann, D., and Finlayson, B. (1989). Calcium-Oxalate Dihydrate
(Weddellite) Precipitation. J. Cryst. Growth 98, 285–292. doi: 10.1016/0022-
0248(89)90143-7
Burns, J. R., and Finlayson, B. (1980). A proposal for a standard reference artificial
urine in in vitro urolithiasis experiments. Invest. Urol. 18, 167–169.
Carey, A. J., Sullivan, M. J., Duell, B. L., Crossman, D. K., Chattopadhyay, D.,
Brooks, A. J., et al. (2016). Uropathogenic Escherichia coli engages CD14-
dependent signaling to enable bladder-macrophage-dependent control of acute
urinary tract infection. J. Infect. Dis. 213, 659–668. doi: 10.1093/infdis/jiv424
Carlsson, S., Wiklund, N. P., Engstrand, L., Weitzberg, E., and Lundberg, J.
O. (2001). Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric
oxide generation and bacterial growth in urine. Nitric Oxide 5, 580–586. doi:
10.1006/niox.2001.0371
Chambers, S. T., and Lever, M. (1996). Betaines and urinary tract infections.
Nephron 74, 1–10. doi: 10.1159/000189274
Chaturvedi, K. S., Hung, C. S., Crowley, J. R., Stapleton, A. E., and Henderson, J.
P. (2012). The siderophore yersiniabactin binds copper to protect pathogens
during infection. Nat. Chem. Biol. 8, 731–736. doi: 10.1038/nchembio.1020
Christmas, K. G., Gower, L. B., Khan, S. R., and El-Shall, H. (2002). Aggregation
and dispersion characteristics of calcium oxalate monohydrate: effect of urinary
species. J. Colloid Interface Sci. 256, 168–174. doi: 10.1006/jcis.2002.8283
Chromek, M., Slamová, Z., Bergman, P., Kovács, L., Podracká, L., Ehrén, I., et al.
(2006). The antimicrobial peptide cathelicidin protects the urinary tract against
invasive bacterial infection. Nat. Med. 12, 636–641. doi: 10.1038/nm1407
Chutipongtanate, S., and Thongboonkerd, V. (2010). Systematic comparisons of
artificial urine formulas for in vitro cellular study.Anal. Biochem. 402, 110–112.
doi: 10.1016/j.ab.2010.03.031
Clarke, M., Pead, L., and Maskell, R. (1985). Urinary infection in adult men:
a laboratory perspective. Br. J. Urol. 57, 222–226. doi: 10.1111/j.1464-
410X.1985.tb06429.x
Cosloy, S. D., and McFall, E. (1973). Metabolism of D-serine in Escherichia coli
K-12: mechanism of growth inhibition. J. Bacteriol. 114, 685–694.
Dalal, S., Nicolle, L., Marrs, C. F., Zhang, L., Harding, G., and Foxman,
B. (2009). Long-term Escherichia coli asymptomatic bacteriuria among
women with diabetes mellitus. Clin. Infect. Dis. 49, 491–497. doi: 10.1086/
600883
Dalhoff, A., Stubbings, W., and Schubert, S. (2011). Comparative in vitro activities
of the novel antibacterial finafloxacin against selected Gram-positive and
Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine.
Antimicrob. Agents Chemother. 55, 1814–1818. doi: 10.1128/AAC.00886-10
Darouiche, R. O., Mansouri, M. D., Gawande, P. V., and Madhyastha, S. (2008).
Efficacy of combination of chlorhexidine and protamine sulphate against
device-associated pathogens. J. Antimicrob. Chemother. 61, 651–657. doi:
10.1093/jac/dkn006
Davis, C. P., Arnett, D., and Warren, M. M. (1982). Iontophoretic killing of
Escherichia coli in static fluid and in a model catheter system. J. Clin. Microbiol.
15, 891–894.
Davis, C. P., Wagle, N., Anderson, M. D., andWarren, M. M. (1991). Bacterial and
fungal killing by iontophoresis with long-lived electrodes. Antimicrob. Agents
Chemother. 35, 2131–2134. doi: 10.1128/AAC.35.10.2131
Davis, C. P., Weinberg, S., Anderson, M. D., Rao, G. M., and Warren, M. M.
(1989). Effects of microamperage, medium, and bacterial concentration on
iontophoretic killing of bacteria in fluid. Antimicrob. Agents Chemother. 33,
442–447. doi: 10.1128/AAC.33.4.442
Decramer, S., Gonzalez de Peredo, A., Breuil, B., Mischak, H., Monsarrat, B.,
Bascands, J. L., et al. (2008). Urine in clinical proteomics.Mol. Cell. Proteomics
7, 1850–1862. doi: 10.1074/mcp.R800001-MCP200
Deutch, C. E., Arballo, M. E., Cooks, L. N., Gomes, J. M., Williams, T.
M., Aboul-Fadl, T., et al. (2006). Susceptibility of Escherichia coli to L-
selenaproline and other L-proline analogues in laboratory culture media and
normal human urine. Lett. Appl. Microbiol. 43, 392–398. doi: 10.1111/j.1472-
765X.2006.01979.x
Dinnbier, U., Limpinsel, E., Schmid, R., and Bakker, E. P. (1988). Transient
accumulation of potassium glutamate and its replacement by trehalose during
adaptation of growing cells of Escherichia coli K-12 to elevated sodium
chloride concentrations. Arch. Microbiol. 150, 348–357. doi: 10.1007/BF004
08306
Domergue, R., Castaño, I., De Las Peñas, A., Zupancic, M., Lockatell, V., Hebel,
J. R., et al. (2005). Nicotinic acid limitation regulates silencing of Candida
adhesins during UTI. Science 308, 866–870. doi: 10.1126/science.1108640
Doremus, R. H., Teich, S., and Silvis, P. X. (1978). Crystallization of calcium oxalate
from synthetic urine. Invest. Urol. 15, 469–472.
Duell, B. L., Carey, A. J., Tan, C. K., Cui, X., Webb, R. I., Totsika, M., et al.
(2012). Innate transcriptional networks activated in bladder in response to
uropathogenic Escherichia coli drive diverse biological pathways and rapid
synthesis of IL-10 for defense against bacterial urinary tract infection.
J. Immunol. 188, 781–792. doi: 10.4049/jimmunol.1101231
Fischer, H., Lutay, N., Ragnarsdóttir, B., Yadav, M., Jönsson, K., Urbano,
A., et al. (2010). Pathogen specific, IRF3-dependent signaling and innate
resistance to human kidney infection. PLoS Pathog. 6:e1001109. doi:
10.1371/journal.ppat.1001109
Frendéus, B., Wachtler, C., Hedlund, M., Fischer, H., Samuelsson, P., Svensson,
M., et al. (2001). Escherichia coli P fimbriae utilize the Toll-like receptor 4
pathway for cell activation. Mol. Microbiol. 40, 37–51. doi: 10.1046/j.1365-
2958.2001.02361.x
Garcia, E. C., Brumbaugh, A. R., and Mobley, H. L. (2011). Redundancy and
specificity of Escherichia coli iron acquisition systems during urinary tract
infection. Infect. Immun. 79, 1225–1235. doi: 10.1128/IAI.01222-10
Gardner, G. L., and Doremus, R. H. (1978). Crystal growth inhibitors in human
urine. Effect on calcium oxalate kinetics. Invest. Urol. 15, 478–485.
Gonzalez-Chavez, S. A., Arevalo-Gallegos, S., and Rascon-Cruz, Q. (2009).
Lactoferrin: structure, function and applications. Int. J. Antimicrob. Agents 33,
301, e301–e308. doi: 10.1016/j.ijantimicag.2008.07.020
Gordon, D. M., and Riley, M. A. (1992). A theoretical and experimental analysis of
bacterial growth in the bladder.Mol. Microbiol. 6, 555–562. doi: 10.1111/j.1365-
2958.1992.tb01500.x
Grases, F., and Llobera, A. (1998). Experimental model to study sedimentary
kidney stones.Micron 29, 105–111. doi: 10.1016/S0968-4328(98)00006-7
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 February 2016 | Volume 6 | Article 14
Ipe et al. Basics of Bacteriuria
Greene, S. E., Hibbing, M. E., Janetka, J., Chen, S. L., and Hultgren, S. J. (2015).
Human urine decreases function and expression of Type 1 pili in uropathogenic
Escherichia coli.MBio 6:e00820. doi: 10.1128/mBio.00820-15
Griffith, D. P., Musher, D. M., and Itin, C. (1976). Urease. The primary cause of
infection-induced urinary stones. Invest. Urol. 13, 346–350.
Grönberg-Hernández, J., Sundén, F., Connolly, J., Svanborg, C., and
Wullt, B. (2011). Genetic control of the variable innate immune
response to asymptomatic bacteriuria. PLoS ONE 6:e28289. doi:
10.1371/journal.pone.0028289
Guo, K., and Li, L. (2009). Differential 12C-/13C-isotope dansylation labeling
and fast liquid chromatography/mass spectrometry for absolute and relative
quantification of the metabolome. Anal. Chem. 81, 3919–3932. doi:
10.1021/ac900166a
Gutierrez, C., Ardourel, M., Bremer, E., Middendorf, A., Boos,W., and Ehmann, U.
(1989). Analysis and DNA sequence of the osmoregulated treA gene encoding
the periplasmic trehalase of Escherichia coliK12.Mol. Gen. Genet. 217, 347–354.
doi: 10.1007/BF02464903
Hagan, E. C., and Mobley, H. L. (2009). Haem acquisition is facilitated by a
novel receptor Hma and required by uropathogenic Escherichia coli for kidney
infection.Mol. Microbiol. 71, 79–91. doi: 10.1111/j.1365-2958.2008.06509.x
Hand, W. L., Smith, J. W., and Sanford, J. P. (1971). The antibacterial effect of
normal and infected urinary bladder. J. Lab. Clin. Med. 77, 605–615.
Hannan, T. J., Mysorekar, I. U., Hung, C. S., Isaacson-Schmid, M. L., and Hultgren,
S. J. (2010). Early severe inflammatory responses to uropathogenic E. coli
predispose to chronic and recurrent urinary tract infection. PLoS Pathog.
6:e1001042. doi: 10.1371/journal.ppat.1001042
Hannan, T. J., Totsika, M., Mansfield, K. J., Moore, K. H., Schembri, M. A., and
Hultgren, S. J. (2012). Host-pathogen checkpoints and population bottlenecks
in persistent and intracellular uropathogenic Escherichia coli bladder infection.
FEMS Microbiol. Rev. 36, 616–648. doi: 10.1111/j.1574-6976.2012.00339.x
Håversen, L. A., Engberg, I., Baltzer, L., Dolphin, G., Hanson, L. A., and Mattsby-
Baltzer, I. (2000). Human lactoferrin and peptides derived from a surface-
exposed helical region reduce experimental Escherichia coli urinary tract
infection in mice. Infect. Immun. 68, 5816–5823. doi: 10.1128/IAI.68.10.5816-
5823.2000
Hood, M. I., and Skaar, E. P. (2012). Nutritional immunity: transition metals
at the pathogen-host interface. Nat. Rev. Microbiol. 10, 525–537. doi:
10.1038/nrmicro2836
Hooton, T. M., Scholes, D., Stapleton, A. E., Roberts, P. L., Winter, C.,
Gupta, K., et al. (2000). A prospective study of asymptomatic bacteriuria
in sexually active young women. N. Engl. J. Med. 343, 992–997. doi:
10.1056/NEJM200010053431402
Hryckowian, A. J., Baisa, G. A., Schwartz, K. J., andWelch, R. A. (2015). dsdA does
not affect colonization of the murine urinary tract by Escherichia coli CFT073.
PLoS ONE 10:e0138121. doi: 10.1371/journal.pone.0138121
Huang, Y., Nishikawa, T., Satoh, K., Iwata, T., Fukushima, T., Santa, T., et al.
(1998). Urinary excretion of D-serine in human: comparison of different ages
and species. Biol. Pharm. Bull. 21, 156–162. doi: 10.1248/bpb.21.156
Hull, R., Rudy, D., Donovan, W., Svanborg, C., Wieser, I., Stewart, C., et al. (2000).
Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord
injured patients. J. Urol. 163, 872–877. doi: 10.1016/S0022-5347(05)67823-8
Ipe, D. S., Ben Zakour, N. L., Sullivan, M. J., Beatson, S. A., Ulett, K. B.,
Benjamin, W. H., et al. (2016). Discovery and characterization of human urine
utilization by asymptomatic bacteriuria streptococcus agalactiae. Infect. Immun.
84, 307–319. doi: 10.1128/IAI.00938-15
Ipe, D. S., Sundac, L., Benjamin, W. H. Jr., Moore, K. H., and Ulett, G. C. (2013).
Asymptomatic bacteriuria: prevalence rates of causal microorganisms, etiology
of infection in different patient populations, and recent advances in molecular
detection. FEMS Microbiol. Lett. 346, 1–10. doi: 10.1111/1574-6968.12204
Isaacson, L. C. (1969). Urinary composition in calcific nephrolithiasis. Invest. Urol.
6, 356–363.
Jain, N., Kohli, R., Cook, E., Gialanella, P., Chang, T., and Fries, B. C. (2007).
Biofilm formation by and antifungal susceptibility of Candida isolates from
urine. Appl. Environ. Microbiol. 73, 1697–1703. doi: 10.1128/AEM.02439-06
Järvisalo, J., Olkinuora, M., Kiilunen, M., Kivistö, H., Ristola, P., Tossavainen,
A., et al. (1992). Urinary and blood manganese in occupationally nonexposed
populations and in manual metal arc welders of mild steel. Int. Arch. Occup.
Environ. Health 63, 495–501. doi: 10.1007/BF00572116
Johnson, J. R., Clabots, C., and Rosen, H. (2006). Effect of inactivation of the
global oxidative stress regulator oxyR on the colonization ability of Escherichia
coli O1:K1:H7 in a mouse model of ascending urinary tract infection. Infect.
Immun. 74, 461–468. doi: 10.1128/IAI.74.1.461-468.2006
King, J. E., Aal Owaif, H. A., Jia, J., and Roberts, I. S. (2015). Phenotypic
heterogeneity in expression of the K1 polysaccharide capsule of uropathogenic
Escherichia coli and downregulation of the capsule genes during growth in
urine. Infect. Immun. 83, 2605–2613. doi: 10.1128/IAI.00188-15
Klemm, P., Hancock, V., and Schembri, M. A. (2007). Mellowing out: adaptation
to commensalism by Escherichia coli asymptomatic bacteriuria strain 83972.
Infect. Immun. 75, 3688–3695. doi: 10.1128/IAI.01730-06
Klemm, P., Roos, V., Ulett, G. C., Svanborg, C., and Schembri, M. A. (2006).
Molecular characterization of the Escherichia coli asymptomatic bacteriuria
strain 83972: the taming of a pathogen. Infect. Immun. 74, 781–785. doi:
10.1128/IAI.74.1.781-785.2006
Kline, K. A., Schwartz, D. J., Gilbert, N. M., Hultgren, S. J., and Lewis, A. L. (2012).
Immune modulation by group B Streptococcus influences host susceptibility
to urinary tract infection by uropathogenic Escherichia coli. Infect. Immun. 80,
4186–4194. doi: 10.1128/IAI.00684-12
Kucheria, R., Dasgupta, P., Sacks, S. H., Khan, M. S., and Sheerin, N. S. (2005).
Urinary tract infections: new insights into a common problem. Postgrad. Med.
J. 81, 83–86. doi: 10.1136/pgmj.2004.023036
Kunin, C. M., Hua, T. H., and Bakaletz, L. O. (1995). Effect of salicylate
on expression of flagella by Escherichia coli and Proteus, Providencia, and
Pseudomonas spp. Infect. Immun. 63, 1796–1799.
Kunin, C. M., Hua, T. H., Guerrant, R. L., and Bakaletz, L. O. (1994). Effect
of salicylate, bismuth, osmolytes, and tetracycline resistance on expression of
fimbriae by Escherichia coli. Infect. Immun. 62, 2178–2186.
Kunin, C. M., Hua, T. H., Van Arsdale White, L., and Villarejo, M. (1992). Growth
of Escherichia coli in human urine: role of salt tolerance and accumulation of
glycine betaine. J. Infect. Dis. 166, 1311–1315. doi: 10.1093/infdis/166.6.1311
Laimins, L. A., Rhoads, D. B., Altendorf, K., and Epstein, W. (1978). Identification
of the structural proteins of an ATP-driven potassium transport system
in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 75, 3216–3219. doi:
10.1073/pnas.75.7.3216
Landete, J. M., García-Haro, L., Blasco, A., Manzanares, P., Berbegal, C.,
Monedero, V., et al. (2010). Requirement of the Lactobacillus caseiMaeKR two-
component system for L-malic acid utilization via a malic enzyme pathway.
Appl. Environ. Microbiol. 76, 84–95. doi: 10.1128/AEM.02145-09
La Rosa, S. L., Diep, D. B., Nes, I. F., and Brede, D. A. (2012). Construction
and application of a luxABCDE reporter system for real-time monitoring of
Enterococcus faecalis gene expression and growth. Appl. Environ. Microbiol. 78,
7003–7011. doi: 10.1128/AEM.02018-12
Lee, S. C., Hutchinson, J. M., Inn, K. G., and Thein, M. (1995). An intercomparison
study of 237Np determination in artificial urine samples. Health Phys. 68,
350–358. doi: 10.1097/00004032-199503000-00007
Lehman, S. M., and Donlan, R. M. (2015). Bacteriophage-mediated control of
a two-species biofilm formed by microorganisms causing catheter-associated
urinary tract infections in an in vitro urinary catheter model. Antimicrob.
Agents Chemother. 59, 1127–1137. doi: 10.1128/AAC.03786-14
Leonhardt, K. O., and Landes, R. R. (1963). Oxygen tension of the urine and renal
structures. Preliminary report of clinical findings.N. Engl. J. Med. 269, 115–121.
doi: 10.1056/NEJM196307182690301
Lomberg, H., Hanson, L. A., Jacobsson, B., Jodal, U., Leﬄer, H., and Edén, C.
S. (1983). Correlation of P blood group, vesicoureteral reflux, and bacterial
attachment in patients with recurrent pyelonephritis. N. Engl. J. Med. 308,
1189–1192. doi: 10.1056/NEJM198305193082003
Low, Y. L., Jakubovics, N. S., Flatman, J. C., Jenkinson, H. F., and Smith, A.
W. (2003). Manganese-dependent regulation of the endocarditis-associated
virulence factor EfaA of Enterococcus faecalis. J. Med. Microbiol. 52, 113–119.
doi: 10.1099/jmm.0.05039-0
Mabbett, A. N., Ulett, G. C., Watts, R. E., Tree, J. J., Totsika, M., Ong, C. L., et al.
(2009). Virulence properties of asymptomatic bacteriuria Escherichia coli. Int. J.
Med. Microbiol. 299, 53–63. doi: 10.1016/j.ijmm.2008.06.003
Mansouri, M. D., and Darouiche, R. O. (2008). In-vitro activity and in-vivo efficacy
of catheters impregnated with chloroxylenol and thymol against uropathogens.
Clin. Microbiol. Infect. 14, 190–192. doi: 10.1111/j.1469-0691.2007.
01894.x
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 February 2016 | Volume 6 | Article 14
Ipe et al. Basics of Bacteriuria
Martino, P. D., Fursy, R., Bret, L., Sundararaju, B., and Phillips, R. S. (2003). Indole
can act as an extracellular signal to regulate biofilm formation of Escherichia
coli and other indole-producing bacteria. Can. J. Microbiol. 49, 443–449. doi:
10.1139/w03-056
Mayrovitz, H. N., and Sims, N. (2001). Biophysical effects of water and synthetic
urine on skin. Adv. Skin Wound Care 14, 302–308. doi: 10.1097/00129334-
200111000-00013
Meury, J., Robin, A., and Monnier-Champeix, P. (1985). Turgor-controlled K+
fluxes and their pathways in Escherichia coli. Eur. J. Biochem. 151, 613–619. doi:
10.1111/j.1432-1033.1985.tb09148.x
Miller, J. D., Randolph, A. D., andDrach, G.W. (1977). Observations upon calcium
oxalate crystallization kinetics in simulated urine. J. Urol. 117, 342–345.
Minuth, J. N., Musher, D. M., and Thorsteinsson, S. B. (1976). Inhibition of the
antibacterial activity of gentamicin by urine. J. Infect. Dis. 133, 14–21. doi:
10.1093/infdis/133.1.14
Negri, M., Silva, S., Breda, D., Henriques, M., Azeredo, J., and Oliveira, R. (2012).
Candida tropicalis biofilms: effect on urinary epithelial cells.Microb. Pathog. 53,
95–99. doi: 10.1016/j.micpath.2012.05.006
Negri, M., Silva, S., Capoci, I. R., Azeredo, J., and Henriques, M. (2015). Candida
tropicalis biofilms: biomass, metabolic activity and secreted aspartyl proteinase
production. Mycopathologia. doi: 10.1007/s11046-015-9964-4. [Epub ahead of
print].
Negri, M., Silva, S., Henriques, M., Azeredo, J., Svidzinski, T., and Oliveira, R.
(2011). Candida tropicalis biofilms: artificial urine, urinary catheters and flow
model.Medical Mycology 49, 739–747. doi: 10.3109/13693786.2011.560619
Nickel, J. C., Ruseska, I., Wright, J. B., and Costerton, J. W. (1985).
Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm
on urinary catheter material. Antimicrob. Agents Chemother. 27, 619–624. doi:
10.1128/AAC.27.4.619
Nicolle, L. E. (1997). Asymptomatic bacteriuria in the elderly. Infect. Dis. Clin.
North Am. 11, 647–662. doi: 10.1016/S0891-5520(05)70378-0
Nicolle, L. E. (1999). Urinary infections in the elderly: symptomatic of
asymptomatic? Int. J. Antimicrob. Agents 11, 265–268.
Nicolle, L. E. (2014). Asymptomatic bacteriuria. Curr. Opin. Infect. Dis. 27, 90–96.
doi: 10.1097/QCO.0000000000000019
Nicolle, L. E., Bradley, S., Colgan, R., Rice, J. C., Schaeffer, A., and Hooton, T. M.
(2005). Infectious Diseases Society of America guidelines for the diagnosis and
treatment of asymptomatic bacteriuria in adults. Clin. Infect. Dis. 40, 643–654.
doi: 10.1086/427507
Nielubowicz, G. R., and Mobley, H. L. (2010). Host-pathogen interactions in
urinary tract infection.Nat. Rev. Urol. 7, 430–441. doi: 10.1038/nrurol.2010.101
O’grady, F., and Cattell, W. R. (1966a). Kinetics of urinary tract infection. I. Upper
urinary tract. Br. J. Urol. 38, 149–155.
O’grady, F., and Cattell, W. R. (1966b). Kinetics of urinary tract infection. II. The
bladder. Br. J. Urol. 38, 156–162.
O’grady, F., and Pennington, J. H. (1966). Bacterial growth in an in vitro system
simulating conditions in the urinary bladder. Br. J. Exp. Pathol. 47, 152–157.
Ong, C. L., Beatson, S. A., McEwan, A. G., and Schembri, M. A. (2009).
Conjugative plasmid transfer and adhesion dynamics in an Escherichia
coli biofilm. Appl. Environ. Microbiol. 75, 6783–6791. doi: 10.1128/AEM.
00974-09
Ong, C. L., Beatson, S. A., Totsika, M., Forestier, C., McEwan, A. G., and Schembri,
M. A. (2010). Molecular analysis of type 3 fimbrial genes from Escherichia coli,
Klebsiella and Citrobacter species. BMC Microbiol. 10:183. doi: 10.1186/1471-
2180-10-183
Opalko, F. J., Adair, J. H., and Khan, S. R. (1997). Heterogeneous
nucleation of calcium oxalate trihydrate in artificial urine by constant
composition. J. Cryst. Growth 181, 410–417. doi: 10.1016/S0022-0248(97)
00222-4
Pätzold, R., Schieber, A., and Brückner, H. (2005). Gas chromatographic
quantification of free D-amino acids in higher vertebrates. Biomed.
Chromatogr. 19, 466–473. doi: 10.1002/bmc.515
Phuengkham, H., and Nasongkla, N. (2015). Development of antibacterial coating
on silicone surface via chlorhexidine-loaded nanospheres. J. Mater. Sci. Mater.
Med. 26:78. doi: 10.1007/s10856-015-5418-2
Putnam, D. F., Company-West, M. D. A., Center, L. R., Aeronautics, U. S. N., and
Administration, S. (1971). Composition and Concentrative Properties of Human
Urine.Washington, DC: National Aeronautics and Space Administration.
Raffi, H. S., Bates, J. M. Jr., Laszik, Z., and Kumar, S. (2005). Tamm-Horsfall protein
acts as a general host-defense factor against bacterial cystitis.Am. J. Nephrol. 25,
570–578. doi: 10.1159/000088990
Ragnarsdóttir, B., and Svanborg, C. (2012). Susceptibility to acute pyelonephritis
or asymptomatic bacteriuria: host-pathogen interaction in urinary tract
infections. Pediatric Nephrol. 27, 2017–2029. doi: 10.1007/s00467-011-2089-1
Rane, H. S., Bernardo, S. M., Howell, A. B., and Lee, S. A. (2014). Cranberry-
derived proanthocyanidins prevent formation of Candida albicans biofilms
in artificial urine through biofilm- and adherence-specific mechanisms.
J. Antimicrob. Chemother. 69, 428–436. doi: 10.1093/jac/dkt398
Robertson, W. G., Peacock, M., and Nordin, B. E. (1968). Activity products in
stone-forming and non-stone-forming urine. Clin. Sci. 34, 579–594.
Robertson, W. G., and Scurr, D. S. (1986). Modifiers of calcium oxalate
crystallization found in urine. I. Studies with a continuous crystallizer using
an artificial urine. J. Urol. 135, 1322–1326.
Robertson, W. G., Scurr, D. S., and Bridge, C. M. (1981). Factors influencing
the crystallization of calcium-oxalate in urine - critique. J. Cryst. Growth 53,
182–194. doi: 10.1016/0022-0248(81)90064-6
Robinson, A. V., Fisher, D. R., and Hadley, R. T. (1984). Technical Evaluation of
Draft ANSI Standard N13.30, Performance Criteria for Radioassay. Richland,
WA: Pacific Northwest Laboratory.
Rodgers, A. L., and Wandt, M. A. (1991). Influence of ageing, pH and various
additives on crystal formation in artificial urine. Scanning Microsc. 5, 697–705.
discussion: 705–696.
Roesch, P. L., Redford, P., Batchelet, S., Moritz, R. L., Pellett, S., Haugen, B.
J., et al. (2003). Uropathogenic Escherichia coli use D-serine deaminase to
modulate infection of the murine urinary tract. Mol. Microbiol. 49, 54–67. doi:
10.1046/j.1365-2958.2003.03543.x
Ronald, A., and Ludwig, E. (2001). Urinary tract infections in adults with diabetes.
Int. J. Antimicrob. Agents 17, 287–292. doi: 10.1016/S0924-8579(00)00356-3
Roos, V., Nielsen, E. M., and Klemm, P. (2006a). Asymptomatic bacteriuria
Escherichia coli strains: adhesins, growth and competition. FEMS Microbiol.
Lett. 262, 22–30. doi: 10.1111/j.1574-6968.2006.00355.x
Roos, V., Ulett, G. C., Schembri, M. A., and Klemm, P. (2006b). The asymptomatic
bacteriuria Escherichia coli strain 83972 outcompetes uropathogenic E. coli
strains in human urine. Infect. Immun. 74, 615–624. doi: 10.1128/IAI.74.1.615-
624.2006
Rose,M. B. (1975). Renal stone formation. The inhibitory effect of urine on calcium
oxalate precipitation. Invest. Urol. 12, 428–433.
Rubin, R. H., Shapiro, E. D., Andriole, V. T., Davis, R. J., and Stamm,
W. E. (1992). Evaluation of new anti-infective drugs for the treatment of
urinary tract infection. Infectious Diseases Society of America and the Food
and Drug Administration. Clin. Infect. Dis. 15(Suppl. 1), S216–S227. doi:
10.1093/clind/15.supplement_1.s216
Rudick, C. N., Billips, B. K., Pavlov, V. I., Yaggie, R. E., Schaeffer, A. J., and
Klumpp, D. J. (2010). Host-pathogen interactions mediating pain of urinary
tract infection. J. Infect. Dis. 201, 1240–1249. doi: 10.1086/651275
Russo, T. A., Jodush, S. T., Brown, J. J., and Johnson, J. R. (1996).
Identification of two previously unrecognized genes (guaA and argC)
important for uropathogenesis. Mol. Microbiol. 22, 217–229. doi:
10.1046/j.1365-2958.1996.00096.x
Russo, T. A., Olson, R., Macdonald, U., Beanan, J., and Davidson, B. A. (2015).
Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the
growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae
ex vivo and in vivo. Infect. Immun. 83, 3325–3333. doi: 10.1128/IAI.
00430-15
Ryall, R. L., Harnett, R. M., Hibberd, C. M., Mazzachi, B. C., Mazzachi, R. D., and
Marshall, V. R. (1987). Urinary risk factors in calcium oxalate stone disease:
comparison of men and women. Br. J. Urol. 60, 480–488. doi: 10.1111/j.1464-
410X.1987.tb05025.x
Säemann, M. D., Weichhart, T., Hörl, W. H., and Zlabinger, G. J. (2005).
Tamm-Horsfall protein: a multilayered defence molecule against urinary
tract infection. Eur. J. Clin. Invest. 35, 227–235. doi: 10.1111/j.1365-
2362.2005.01483.x
Sakinç, T., Michalski, N., Kleine, B., and Gatermann, S. G. (2009). The
uropathogenic species Staphylococcus saprophyticus tolerates a high
concentration of D-serine. FEMS Microbiol. Lett. 299, 60–64. doi:
10.1111/j.1574-6968.2009.01731.x
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 10 February 2016 | Volume 6 | Article 14
Ipe et al. Basics of Bacteriuria
Sako, S., Kariyama, R., Mitsuhata, R., Yamamoto, M., Wada, K., Ishii, A., et al.
(2014). Molecular epidemiology and clinical implications of metallo-beta-
lactamase-producing Pseudomonas aeruginosa isolated from urine. Acta Med.
Okayama 68, 89–99.
Salvador, E.,Wagenlehner, F., Kohler, C. D.,Mellmann, A., Hacker, J., Svanborg, C.,
et al. (2012). Comparison of asymptomatic bacteriuria Escherichia coli isolates
from healthy individuals versus those from hospital patients shows that long-
term bladder colonization selects for attenuated virulence phenotypes. Infect.
Immun. 80, 668–678. doi: 10.1128/IAI.06191-11
Samaranayake, Y. H., Bandara, H. M., Cheung, B. P., Yau, J. Y., Yeung, S. K., and
Samaranayake, L. P. (2014). Enteric Gram-negative bacilli suppress Candida
biofilms on Foley urinary catheters. APMIS 122, 47–58. doi: 10.1111/apm.
12098
Sarada, B., and Satyanarayana, U. (1991). Urinary composition in men and women
and the risk of urolithiasis. Clin. Biochem. 24, 487–490. doi: 10.1016/S0009-
9120(05)80007-4
Schneeberger, C., Geerlings, S. E., Middleton, P., and Crowther, C. A.
(2012). Interventions for preventing recurrent urinary tract infection
during pregnancy. Cochrane Database Syst. Rev. 11:CD009279. doi:
10.1002/14651858.CD009279.pub2
Schneeberger, C., Kazemier, B. M., and Geerlings, S. E. (2014). Asymptomatic
bacteriuria and urinary tract infections in special patient groups: women with
diabetes mellitus and pregnant women. Curr. Opin. Infect. Dis. 27, 108–114.
doi: 10.1097/QCO.0000000000000028
Shaykhutdinov, R. A., Macinnis, G. D., Dowlatabadi, R., Weljie, A. M., and Vogel,
H. J. (2009). Quantitative analysis of metabolite concentrations in human urine
samples using 13C{1H} NMR spectroscopy. Metabolomics 5, 307–317. doi:
10.1007/s11306-009-0155-5
Sheewin, N. S. (2011). Urinary tract infection. Medicine 39, 384–389. doi:
10.1016/j.mpmed.2011.04.003
Shepard, B. D., and Gilmore, M. S. (2002). Differential expression of virulence-
related genes in Enterococcus faecalis in response to biological cues in serum
and urine. Infect. Immun. 70, 4344–4352. doi: 10.1128/IAI.70.8.4344-4352.2002
Shields-Cutler, R. R., Crowley, J. R., Hung, C. S., Stapleton, A. E., Aldrich,
C. C., Marschall, J., et al. (2015). Human urinary composition controls
antibacterial activity of siderocalin. J. Biol. Chem. 290, 15949–15960. doi:
10.1074/jbc.M115.645812
Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D., and Azeredo, J.
(2010). Silicone colonization by non-Candida albicans Candida species in the
presence of urine. J. Med. Microbiol. 59, 747–754. doi: 10.1099/jmm.0.017517-0
Snyder, J. A., Haugen, B. J., Buckles, E. L., Lockatell, C. V., Johnson, D. E.,
Donnenberg, M. S., et al. (2004). Transcriptome of uropathogenic Escherichia
coli during urinary tract infection. Infect. Immun. 72, 6373–6381. doi:
10.1128/IAI.72.11.6373-6381.2004
Sobel, J. D. (1985). New aspects of pathogenesis of lower urinary tract infections.
Urology 26, 11–16.
Soler-García, A. A., Johnson, D., Hathout, Y., and Ray, P. E. (2009). Iron-
related proteins: candidate urine biomarkers in childhood HIV-associated
renal diseases. Clin. J. Am. Soc. Nephrol. 4, 763–771. doi: 10.2215/CJN.
0200608
Stamey, T. A., and Mihara, G. (1980). Observations on the growth of urethral and
vaginal bacteria in sterile urine. J. Urol. 124, 461–463.
Storer, M. K., Hibbard-Melles, K., Davis, B., and Scotter, J. (2011). Detection of
volatile compounds produced by microbial growth in urine by selected ion
flow tubemass spectrometry (SIFT-MS). J. Microbiol. Methods 87, 111–113. doi:
10.1016/j.mimet.2011.06.012
Strøm, A. R., and Kaasen, I. (1993). Trehalose metabolism in Escherichia coli: stress
protection and stress regulation of gene expression.Mol. Microbiol. 8, 205–210.
doi: 10.1111/j.1365-2958.1993.tb01564.x
Styrvold, O. B., and Strøm, A. R. (1991). Synthesis, accumulation, and excretion
of trehalose in osmotically stressed Escherichia coli K-12 strains: influence of
amber suppressors and function of the periplasmic trehalase. J. Bacteriol. 173,
1187–1192.
Sundén, F., Håkansson, L., Ljunggren, E., and Wullt, B. (2006). Bacterial
interference–is deliberate colonization with Escherichia coli 83972 an
alternative treatment for patients with recurrent urinary tract infection? Int.
J. Antimicrob. Agents 28(Suppl. 1), S26–S29. doi: 10.1016/j.ijantimicag.2006.
05.007
Svanborg, C., Bergsten, G., Fischer, H., Godaly, G., Gustafsson, M., Karpman,
D., et al. (2006). Uropathogenic Escherichia coli as a model of host-parasite
interaction. Curr. Opin. Microbiol. 9, 33–39. doi: 10.1016/j.mib.2005.12.012
Tan, C. K., Carey, A. J., Cui, X., Webb, R. I., Ipe, D., Crowley, M., et al.
(2012). Genome-wide mapping of cystitis due to Streptococcus agalactiae and
Escherichia coli in mice identifies a unique bladder transcriptome that signifies
pathogen-specific antimicrobial defense against urinary tract infection. Infect.
Immun. 80, 3145–3160. doi: 10.1128/IAI.00023-12
Tasevska, N., Runswick, S. A., McTaggart, A., and Bingham, S. A. (2005). Urinary
sucrose and fructose as biomarkers for sugar consumption. Cancer Epidemiol.
Biomarkers Prevent. 14, 1287–1294. doi: 10.1158/1055-9965.EPI-04-0827
Tielen, P., Rosin, N., Meyer, A. K., Dohnt, K., Haddad, I., Jänsch, L., et al.
(2013). Regulatory and metabolic networks for the adaptation of Pseudomonas
aeruginosa biofilms to urinary tract-like conditions. PLoS ONE 8:e71845. doi:
10.1371/journal.pone.0071845
Torffvit, O., and Agardh, C. D. (1993). Tubular secretion of Tamm-Horsfall protein
is decreased in type 1 (insulin-dependent) diabetic patients with diabetic
nephropathy. Nephron 65, 227–231. doi: 10.1159/000187479
Torzewska, A., Budzynska, A., Bialczak-Kokot, M., and Rózalski, A. (2014). In
vitro studies of epithelium-associated crystallization caused by uropathogens
during urinary calculi development. Microb. Pathog. 71–72, 25–31. doi:
10.1016/j.micpath.2014.04.007
Torzewska, A., and Rózalski, A. (2014). In vitro studies on the role of
glycosaminoglycans in crystallization intensity during infectious urinary stones
formation. APMIS 122, 505–511. doi: 10.1111/apm.12191
Torzewska, A., and Rózalski, A. (2015). Various intensity of Proteus mirabilis-
induced crystallization resulting from the changes in the mineral composition
of urine. Acta Biochim. Pol. 62, 127–132. doi: 10.18388/abp.2014_882
Torzewska, A., Staczek, P., and Rózalski, A. (2003). Crystallization of urine
mineral components may depend on the chemical nature of Proteus endotoxin
polysaccharides. J. Med. Microbiol. 52, 471–477. doi: 10.1099/jmm.0.05161-0
Ulett, G. C., Totsika, M., Schaale, K., Carey, A. J., Sweet, M. J., and Schembri,
M. A. (2013). Uropathogenic Escherichia coli virulence and innate immune
responses during urinary tract infection. Curr. Opin. Microbiol. 16, 100–107.
doi: 10.1016/j.mib.2013.01.005
Uppuluri, P., Dinakaran, H., Thomas, D. P., Chaturvedi, A. K., and Lopez-
Ribot, J. L. (2009). Characteristics of Candida albicans biofilms grown in a
synthetic urine medium. J. Clin. Microbiol. 47, 4078–4083. doi: 10.1128/JCM.
01377-09
Vebø, H. C., Solheim, M., Snipen, L., Nes, I. F., and Brede, D. A. (2010).
Comparative genomic analysis of pathogenic and probiotic Enterococcus
faecalis isolates, and their transcriptional responses to growth in human urine.
PLoS ONE 5:e12489. doi: 10.1371/journal.pone.0012489
Vejborg, R. M., de Evgrafov, M. R., Phan, M. D., Totsika, M., Schembri, M.
A., and Hancock, V. (2012). Identification of genes important for growth
of asymptomatic bacteriuria Escherichia coli in urine. Infect. Immun. 80,
3179–3188. doi: 10.1128/IAI.00473-12
Watts, R. E., Hancock, V., Ong, C. L., Vejborg, R. M., Mabbett, A. N.,
Totsika, M., et al. (2010). Escherichia coli isolates causing asymptomatic
bacteriuria in catheterized and noncatheterized individuals possess similar
virulence properties. J. Clin. Microbiol. 48, 2449–2458. doi: 10.1128/JCM.
01611-09
Watts, R. E., Tan, C. K., Ulett, G. C., Carey, A. J., Totsika,M., Idris, A., et al. (2012a).
Escherichia coli 83972 expressing a P fimbriae oligosaccharide receptor mimic
impairs adhesion of uropathogenic E. coli. J. Infect. Dis. 206, 1242–1249. doi:
10.1093/infdis/jis493
Watts, R. E., Totsika, M., Challinor, V. L., Mabbett, A. N., Ulett, G. C., De Voss,
J. J., et al. (2012b). Contribution of siderophore systems to growth and urinary
tract colonization of asymptomatic bacteriuria Escherichia coli. Infect. Immun.
80, 333–344. doi: 10.1128/IAI.05594-11
Weinberg, E. D. (1978). Iron and infection.Microbiol. Rev. 42, 45–66.
Wenzler-Röttele, S., Dettenkofer, M., Schmidt-Eisenlohr, E., Gregersen, A.,
Schulte-Monting, J., and Tvede, M. (2006). Comparison in a laboratory model
between the performance of a urinary closed system bag with double non-
return valve and that of a single valve system. Infection 34, 214–218. doi:
10.1007/s15010-006-5626-2
Wernli, L., Bonkat, G., Gasser, T. C., Bachmann, A., and Braissant, O. (2013).
Use of isothermal microcalorimetry to quantify the influence of glucose and
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11 February 2016 | Volume 6 | Article 14
Ipe et al. Basics of Bacteriuria
antifungals on the growth of Candida albicans in urine. J. Appl. Microbiol. 115,
1186–1193. doi: 10.1111/jam.12306
Wilks, S. A., Fader, M. J., and Keevil, C. W. (2015). Novel insights into the Proteus
mirabilis crystalline biofilm using real-time imaging. PLoS ONE 10:e0141711.
doi: 10.1371/journal.pone.0141711
Wishart, D. S., Knox, C., Guo, A. C., Eisner, R., Young, N., Gautam, B., et al. (2009).
HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 37,
D603–D610. doi: 10.1093/nar/gkn810
Wullt, B. (2003). The role of P fimbriae for Escherichia coli establishment and
mucosal inflammation in the human urinary tract. Int. J. Antimicrob. Agents
21, 605–621. doi: 10.1016/S0924-8579(02)00328-X
Wullt, B., Connell, H., Röllano, P., Månsson, W., Colleen, S., and Svanborg,
C. (1998). Urodynamic factors influence the duration of Escherichia coli
bacteriuria in deliberately colonized cases. J. Urol. 159, 2057–2062. doi:
10.1016/S0022-5347(01)63246-4
Zdziarski, J., Brzuszkiewicz, E., Wullt, B., Liesegang, H., Biran, D.,
Voigt, B., et al. (2010). Host imprints on bacterial genomes–rapid,
divergent evolution in individual patients. PLoS Pathog. 6:e1001078. doi:
10.1371/journal.ppat.1001078
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Ipe, Horton and Ulett. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 12 February 2016 | Volume 6 | Article 14
